Answers are grounded in this paper and cite their sources.
Patients should have confidence that the generic drugs they are prescribed in the United States can be effectively substituted for the brand product or another generic product. Through new bioequivalence study designs for narrow therapeutic index (NTI) drugs and postapproval studies of generic substitution, the US Food and Drug Administration's (FDA's) ongoing generic drug regulatory science activities are designed to ensure successful generic substitution for all drug products.
No takes yet. Share an insight, caveat, or question.
Lionberger et al. (2013) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: